Litcius/Paper detail

Low rate of seroconversion after mRNA anti-SARS-CoV-2 vaccination in patients with hematological malignancies

Daniel Ré, Jérôme Barrière, Emmanuel Chamorey, Margaux Delforge, Lauris Gastaud, Emmanuel Petit, Axel Chaminade, Benjamin Verrière, Frédéric Peyrade

2021Leukemia & lymphoma/Leukemia and lymphoma45 citationsDOI

Abstract

Click to increase image sizeClick to decrease image size Disclosure statementNo potential conflict of interest was reported by the author(s).Author contributionsDrs Re, Barrière, Chamorey, and Peyrade had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: all authors. Acquisition, analysis, or interpretation of data: all authors. Drafting of the manuscript: Dr Re. Critical revision of the manuscript for important intellectual content: all authors. Statistical analysis: Dr Chamorey. Administrative, technical, or material support: all authors. Supervision: Drs Re and Barrière.

Topics & Concepts

SeroconversionMedicineVaccinationVirologyImmunologyOncologyInternal medicineAntibodySARS-CoV-2 and COVID-19 ResearchRNA Interference and Gene DeliveryImmunotherapy and Immune Responses